{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:27:33Z","timestamp":1791638853046,"version":"4.3.4"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/21674-0"],"award-info":[{"award-number":["2017\/21674-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/21674-0"],"award-info":[{"award-number":["2017\/21674-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The antinociceptive effect of BoNT-A have been well documented in animal studies; however, results of few but well-designed randomized placebo-controlled clinical trials about BoNT-A efficacy in masticatory myofascial pain (MFP) are inconsistent. Therefore, the present randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy of BoNT-A in patients with refractory MFP. Twenty-eight patients with pain reduction of less than 30% despite conservative treatment and with an average pain intensity of\u2009&gt;\u200950\u00a0mm on the visual analogue scale (VAS) participated. Patients were randomly assigned to receive a total of 80\u00a0U of BoNT-A or saline solution (SS) injected into the masseter and anterior temporalis muscles. Pain intensity (VAS), quantitative sensory testing (QST), conditioned pain modulation (CPM), and psychosocial status were examined. Follow-up was performed at 1 and 6\u00a0months. For repeated-measure comparisons between evaluation times, Friedman test with Bonferroni correction was used for pain and somatosensory variables and the Wilcoxon test for the psychosocial variables. The Mann\u2013Whitney test was used for all comparisons between groups. The BoNT-A group had a significant decrease in pain intensity at follow-ups compared with the SS group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). QST assessment revealed higher pressure pain threshold values in the masseter muscle for BoNT-A group compared to SS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.03) at all follow-ups. No differences were found for mechanical pain threshold and wind-up ratio values (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05) in the entire study. The BoNT-A group presented the most efficient CPM effect (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.03) only at the 1\u00a0month follow-up in the masseter muscle. There was a significant time effect for BoNT-A in all psychosocial variables (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and a drug effect in the Central Sensitization Inventory (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), Pittsburgh Sleep Quality Index (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.004), and Healthy Survey 36 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) at 6\u00a0months follow-up. The study demonstrates that a single injection-session of BoNT-A has positive effects on the hall pain spectrum of patients with refractory masticatory myofascial pain.<\/jats:p>","DOI":"10.1038\/s41598-024-54906-z","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T12:04:44Z","timestamp":1708430684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Botulinum toxin-A effects on pain, somatosensory and psychosocial features of patients with refractory masticatory myofascial pain: a randomized double-blind clinical trial"],"prefix":"10.1038","volume":"14","author":[{"given":"Giancarlo","family":"De la Torre Canales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Lorenzi","family":"Poluha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Rigoldi","family":"Bonjardim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Ernberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo C\u00e9sar Rodrigues","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"issue":"1\u20133","key":"54906_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.pain.2009.08.010","volume":"147","author":"DB Pfau","year":"2009","unstructured":"Pfau, D. B. et al. Somatosensory profiles in subgroups of patients with myogenic temporomandibular disorders and fibromyalgia syndrome. PAIN\u00ae 147(1\u20133), 72\u201383 (2009).","journal-title":"PAIN\u00ae"},{"issue":"11","key":"54906_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.pmrj.2013.06.006","volume":"5","author":"LH Gerber","year":"2013","unstructured":"Gerber, L. H. et al. A systematic comparison between subjects with no pain and pain associated with active myofascial trigger points. PM&R 5(11), 931\u2013938 (2013).","journal-title":"PM&R"},{"issue":"5","key":"54906_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00784-010-0444-4","volume":"15","author":"D Manfredini","year":"2011","unstructured":"Manfredini, D. et al. Correlation of RDC\/TMD axis I diagnoses and axis II pain-related disability. A multicenter study. Clin. Oral Investig. 15(5), 749\u2013756 (2011).","journal-title":"Clin. Oral Investig."},{"issue":"6","key":"54906_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1365-2842.2010.02089.x","volume":"37","author":"T List","year":"2010","unstructured":"List, T. & Axelsson, S. Management of TMD: Evidence from systematic reviews and meta-analyses. J. Oral Rehabil. 37(6), 430\u2013451 (2010).","journal-title":"J. Oral Rehabil."},{"issue":"1","key":"54906_CR5","first-page":"9","volume":"17","author":"P Rammelsberg","year":"2003","unstructured":"Rammelsberg, P. et al. Longitudinal outcome of temporomandibular disorders: A 5-year epidemiologic study of muscle disorders defined by research diagnostic criteria for temporomandibular disorders. J. Orofac. Pain 17(1), 9\u201320 (2003).","journal-title":"J. Orofac. Pain"},{"issue":"10","key":"54906_CR6","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1212\/WNL.56.10.1290","volume":"56","author":"L Foster","year":"2001","unstructured":"Foster, L. et al. Botulinum toxin A and chronic low back pain: A randomized, double-blind study. Neurology 56(10), 1290\u20131293 (2001).","journal-title":"Neurology"},{"issue":"7","key":"54906_CR7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"H Diener","year":"2010","unstructured":"Diener, H. et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7), 804\u2013814 (2010).","journal-title":"Cephalalgia"},{"issue":"6","key":"54906_CR8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S1474-4422(16)00017-X","volume":"15","author":"N Attal","year":"2016","unstructured":"Attal, N. et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 15(6), 555\u2013565 (2016).","journal-title":"Lancet Neurol."},{"issue":"2","key":"54906_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/toxins12020110","volume":"12","author":"C-L Chen","year":"2020","unstructured":"Chen, C.-L. & Meng, E. Can botulinum toxin A play a role in treatment of chronic pelvic pain syndrome in female patients?\u2014Clinical and animal evidence. Toxins 12(2), 110 (2020).","journal-title":"Toxins"},{"issue":"6","key":"54906_CR10","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1097\/00002508-200211001-00003","volume":"18","author":"JC Arezzo","year":"2002","unstructured":"Arezzo, J. C. Possible mechanisms for the effects of botulinum toxin on pain. Clin. J. Pain 18(6), S125\u2013S132 (2002).","journal-title":"Clin. J. Pain"},{"issue":"1\u20132","key":"54906_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","volume":"107","author":"M Cui","year":"2004","unstructured":"Cui, M. et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107(1\u20132), 125\u2013133 (2004).","journal-title":"Pain"},{"key":"54906_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.toxicon.2017.02.010","volume":"129","author":"VRMM Lora","year":"2017","unstructured":"Lora, V. R. M. M. et al. Botulinum toxin type A reduces inflammatory hypernociception induced by arthritis in the temporomadibular joint of rats. Toxicon 129, 52\u201357 (2017).","journal-title":"Toxicon"},{"issue":"8","key":"54906_CR13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/toxins11080459","volume":"11","author":"I Matak","year":"2019","unstructured":"Matak, I. et al. Mechanisms of botulinum toxin type A action on pain. Toxins 11(8), 459 (2019).","journal-title":"Toxins"},{"issue":"2","key":"54906_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.pbb.2009.08.012","volume":"94","author":"L Bach-Rojecky","year":"2009","unstructured":"Bach-Rojecky, L. & Lackovi\u0107, Z. Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol. Biochem. Behav. 94(2), 234\u2013238 (2009).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"54906_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.neuroscience.2011.04.026","volume":"186","author":"I Matak","year":"2011","unstructured":"Matak, I. et al. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 186, 201\u2013207 (2011).","journal-title":"Neuroscience"},{"issue":"6","key":"54906_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00702-013-1150-6","volume":"121","author":"V Drinovac","year":"2014","unstructured":"Drinovac, V., Bach-Rojecky, L. & Lackovi\u0107, Z. Association of antinociceptive action of botulinum toxin type A with GABA-A receptor. J Neural Transm 121(6), 665\u2013669 (2014).","journal-title":"J Neural Transm"},{"key":"54906_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.toxicon.2020.08.027","volume":"187","author":"VRM Mu\u00f1oz-Lora","year":"2020","unstructured":"Mu\u00f1oz-Lora, V. R. M. et al. Modulatory effect of botulinum toxin type A on the microglial P2X7\/CatS\/FKN activated-pathway in antigen-induced arthritis of the temporomandibular joint of rats. Toxicon 187, 116\u2013121 (2020).","journal-title":"Toxicon"},{"issue":"1","key":"54906_CR18","first-page":"39","volume":"101","author":"J Von Lindern","year":"2001","unstructured":"Von Lindern, J. Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction. Acta Neurol Belg 101(1), 39\u201341 (2001).","journal-title":"Acta Neurol Belg"},{"issue":"3","key":"54906_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0304-3959(02)00240-3","volume":"99","author":"DR Nixdorf","year":"2002","unstructured":"Nixdorf, D. R., Heo, G. & Major, P. W. Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain 99(3), 465\u2013473 (2002).","journal-title":"Pain"},{"issue":"8","key":"54906_CR20","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.joms.2008.03.008","volume":"66","author":"C Kurtoglu","year":"2008","unstructured":"Kurtoglu, C. et al. Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg 66(8), 1644\u20131651 (2008).","journal-title":"J Oral Maxillofac Surg"},{"issue":"9","key":"54906_CR21","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/j.pain.2011.03.036","volume":"152","author":"M Ernberg","year":"2011","unstructured":"Ernberg, M. et al. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study. Pain 152(9), 1988\u20131996 (2011).","journal-title":"Pain"},{"issue":"4","key":"54906_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1177\/0003489417693013","volume":"126","author":"AA Patel","year":"2017","unstructured":"Patel, A. A., Lerner, M. Z. & Blitzer, A. IncobotulinumtoxinA injection for temporomandibular joint disorder: A randomized controlled pilot study. Ann. Otol. Rhinol. Laryngol. 126(4), 328\u2013333 (2017).","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"issue":"6","key":"54906_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/toxins12060395","volume":"12","author":"CG De la Torre","year":"2020","unstructured":"De la Torre, C. G. et al. Efficacy and safety of botulinum toxin type a on persistent myofascial pain: A randomized clinical trial. Toxins 12(6), 395 (2020).","journal-title":"Toxins"},{"issue":"9","key":"54906_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41415-019-0257-z","volume":"226","author":"J Patel","year":"2019","unstructured":"Patel, J., Cardoso, J. A. & Mehta, S. A systematic review of botulinum toxin in the management of patients with temporomandibular disorders and bruxism. Br. Dent. J. 226(9), 667\u2013672 (2019).","journal-title":"Br. Dent. J."},{"issue":"9","key":"54906_CR25","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1007\/s00784-019-03026-4","volume":"23","author":"CG De la Torre","year":"2019","unstructured":"De la Torre, C. G. et al. Botulinum toxin type A applications for masticatory myofascial pain and trigeminal neuralgia: What is the evidence regarding adverse effects?. Clin. Oral Investig. 23(9), 3411\u20133421 (2019).","journal-title":"Clin. Oral Investig."},{"issue":"6","key":"54906_CR26","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/joor.13326","volume":"49","author":"M Owen","year":"2022","unstructured":"Owen, M. et al. Impact of botulinum toxin injection into the masticatory muscles on mandibular bone: A systematic review. J. Oral Rehabil. 49(6), 644\u2013653 (2022).","journal-title":"J. Oral Rehabil."},{"issue":"1","key":"54906_CR27","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.11607\/ofph.3023","volume":"36","author":"R Delcanho","year":"2022","unstructured":"Delcanho, R. et al. Botulinum toxin for treating temporomandibular disorders: What is the evidence?. J. Oral Facial Pain Headache 36(1), 3023 (2022).","journal-title":"J. Oral Facial Pain Headache"},{"issue":"2","key":"54906_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.17219\/dmp\/145759","volume":"59","author":"RM Ramos-Herrada","year":"2022","unstructured":"Ramos-Herrada, R. M. et al. Effects of botulinum toxin in patients with myofascial pain related to temporomandibular joint disorders: A systematic review. Dent. Med. Probl. 59(2), 271\u2013280 (2022).","journal-title":"Dent. Med. Probl."},{"issue":"3","key":"54906_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.pain.2003.08.001","volume":"106","author":"DC Turk","year":"2003","unstructured":"Turk, D. C. et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 106(3), 337\u2013345 (2003).","journal-title":"Pain"},{"issue":"1","key":"54906_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-016-0632-y","volume":"17","author":"G Yang","year":"2016","unstructured":"Yang, G. et al. Somatosensory abnormalities in Chinese patients with painful temporomandibular disorders. J. Headache Pain 17(1), 1\u201311 (2016).","journal-title":"J. Headache Pain"},{"issue":"3","key":"54906_CR31","first-page":"274","volume":"64","author":"D Ranoux","year":"2008","unstructured":"Ranoux, D. et al. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc. 64(3), 274\u2013283 (2008).","journal-title":"Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc."},{"issue":"1","key":"54906_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.11607\/jop.1151","volume":"28","author":"E Schiffman","year":"2014","unstructured":"Schiffman, E. et al. Diagnostic criteria for temporomandibular disorders (DC\/TMD) for clinical and research applications: Recommendations of the International RDC\/TMD consortium network and orofacial pain special interest group. J. Oral Fac. Pain Headache 28(1), 6 (2014).","journal-title":"J. Oral Fac. Pain Headache"},{"issue":"10","key":"54906_CR33","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.pain.2011.07.005","volume":"152","author":"MA Ferreira-Valente","year":"2011","unstructured":"Ferreira-Valente, M. A., Pais-Ribeiro, J. L. & Jensen, M. P. Validity of four pain intensity rating scales. PAIN\u00ae 152(10), 2399\u20132404 (2011).","journal-title":"PAIN\u00ae"},{"issue":"2","key":"54906_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar, J. T. et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94(2), 149\u2013158 (2001).","journal-title":"Pain"},{"key":"54906_CR35","unstructured":"Domingues, L., Cruz, E. B. Adapta\u00e7\u00e3o cultural e contributo para a valida\u00e7\u00e3o da escala patient global impression of change. Ifisionline (2011)."},{"issue":"4","key":"54906_CR36","first-page":"347","volume":"9","author":"P Svensson","year":"1995","unstructured":"Svensson, P. et al. Effect of chronic and experimental jaw muscle pain on pain-pressure thresholds and stimulus-response curves. J. Orofac. Pain 9(4), 347 (1995).","journal-title":"J. Orofac. Pain"},{"issue":"8","key":"54906_CR37","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0003-9969(01)00028-0","volume":"46","author":"P Svensson","year":"2001","unstructured":"Svensson, P., Burgaard, A. & Schlosser, S. Fatigue and pain in human jaw muscles during a sustained, low-intensity clenching task. Arch. Oral Biol. 46(8), 773\u2013777 (2001).","journal-title":"Arch. Oral Biol."},{"issue":"11","key":"54906_CR38","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jpain.2009.04.017","volume":"10","author":"C Fern\u00e1ndez-de-las-Pe\u00f1as","year":"2009","unstructured":"Fern\u00e1ndez-de-las-Pe\u00f1as, C. et al. Bilateral widespread mechanical pain sensitivity in women with myofascial temporomandibular disorder: Evidence of impairment in central nociceptive processing. J. Pain 10(11), 1170\u20131178 (2009).","journal-title":"J. Pain"},{"issue":"2","key":"54906_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3109\/08990220.2013.869493","volume":"31","author":"G Yang","year":"2014","unstructured":"Yang, G. et al. A study on variability of quantitative sensory testing in healthy participants and painful temporomandibular disorder patients. Somatosens Mot Res 31(2), 62\u201371 (2014).","journal-title":"Somatosens Mot Res"},{"issue":"1","key":"54906_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejpain.2005.02.003","volume":"10","author":"R Rolke","year":"2006","unstructured":"Rolke, R. et al. Quantitative sensory testing: A comprehensive protocol for clinical trials. Eur J Pain 10(1), 77\u201388 (2006).","journal-title":"Eur J Pain"},{"issue":"3","key":"54906_CR41","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.pain.2006.01.041","volume":"123","author":"R Rolke","year":"2006","unstructured":"Rolke, R. et al. Quantitative sensory testing in the German research network on neuropathic pain (DFNS): Standardized protocol and reference values. Pain 123(3), 231\u2013243 (2006).","journal-title":"Pain"},{"issue":"6","key":"54906_CR42","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/ejp.605","volume":"19","author":"D Yarnitsky","year":"2015","unstructured":"Yarnitsky, D. et al. Recommendations on practice of conditioned pain modulation (CPM) testing. Eur J Pain 19(6), 805\u2013806 (2015).","journal-title":"Eur J Pain"},{"key":"54906_CR43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12883-016-0650-z","volume":"16","author":"J Gehling","year":"2016","unstructured":"Gehling, J. et al. Short-term test-retest-reliability of conditioned pain modulation using the cold-heat-pain method in healthy subjects and its correlation to parameters of standardized quantitative sensory testing. BMC Neurol 16, 125 (2016).","journal-title":"BMC Neurol"},{"issue":"2","key":"54906_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/13548500500524088","volume":"12","author":"J Pais-Ribeiro","year":"2007","unstructured":"Pais-Ribeiro, J. et al. Validation study of a Portuguese version of the hospital anxiety and depression scale. Psychol. Health Med. 12(2), 225\u2013235 (2007).","journal-title":"Psychol. Health Med."},{"key":"54906_CR45","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.2147\/JPR.S131479","volume":"10","author":"W Caumo","year":"2017","unstructured":"Caumo, W. et al. The central sensitization inventory validated and adapted for a Brazilian population: Psychometric properties and its relationship with brain-derived neurotrophic factor. J. Pain Res. 10, 2109\u20132122 (2017).","journal-title":"J. Pain Res."},{"issue":"4","key":"54906_CR46","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1590\/S0034-89102007000400015","volume":"41","author":"CD Luft","year":"2007","unstructured":"Luft, C. D. et al. Brazilian version of the perceived stress scale: Translation and validation for the elderly. Rev. Saude Publica 41(4), 606\u2013615 (2007).","journal-title":"Rev. Saude Publica"},{"issue":"1","key":"54906_CR47","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.sleep.2010.04.020","volume":"12","author":"AN Bertolazi","year":"2011","unstructured":"Bertolazi, A. N. et al. Validation of the Brazilian Portuguese version of the pittsburgh sleep quality index. Sleep Med. 12(1), 70\u201375 (2011).","journal-title":"Sleep Med."},{"issue":"11","key":"54906_CR48","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1111\/j.1526-4637.2012.01492.x","volume":"13","author":"F Sehn","year":"2012","unstructured":"Sehn, F. et al. Cross-cultural adaptation and validation of the Brazilian Portuguese version of the pain catastrophizing scale. Pain Med. 13(11), 1425\u20131435 (2012).","journal-title":"Pain Med."},{"issue":"2","key":"54906_CR49","first-page":"e1","volume":"32","author":"FS Sampaio Bonaf\u00e9","year":"2017","unstructured":"Sampaio Bonaf\u00e9, F. S., Mar\u00f4co, J. & Duarte Bonini Campos, J. A. Cross-cultural validation of the Brazilian Portuguese version of the pain vigilance and awareness questionnaire. J. Oral Fac. Pain Headache 32(2), e1\u2013e12 (2017).","journal-title":"J. Oral Fac. Pain Headache"},{"issue":"4","key":"54906_CR50","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1590\/S1415-790X2013000400009","volume":"16","author":"J Laguardia","year":"2013","unstructured":"Laguardia, J. et al. Brazilian normative data for the Short Form 36 questionnaire, version 2. Rev. Bras. Epidemiol. 16(4), 889\u2013897 (2013).","journal-title":"Rev. Bras. Epidemiol."},{"issue":"2","key":"54906_CR51","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/fampra\/cmac117","volume":"40","author":"C de Moel-Mandel","year":"2023","unstructured":"de Moel-Mandel, C. Understanding and communicating epidemiological measures of risk and benefit. Fam. Pract. 40(2), 423\u2013425 (2023).","journal-title":"Fam. Pract."},{"issue":"1","key":"54906_CR52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/toxins13010006","volume":"13","author":"J-F Montes-Carmona","year":"2020","unstructured":"Montes-Carmona, J.-F., Gonzalez-Perez, L.-M. & Infante-Cossio, P. Treatment of localized and referred masticatory myofascial pain with botulinum toxin injection. Toxins 13(1), 6 (2020).","journal-title":"Toxins"},{"issue":"4","key":"54906_CR53","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4097\/kja.21165","volume":"74","author":"CY Lim","year":"2021","unstructured":"Lim, C. Y. & In, J. Considerations for crossover design in clinical study. Korean J. Anesthesiol. 74(4), 293\u2013299 (2021).","journal-title":"Korean J. Anesthesiol."},{"issue":"3","key":"54906_CR54","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0304-3959(00)00339-0","volume":"88","author":"JT Farrar","year":"2000","unstructured":"Farrar, J. T. et al. Defining the clinically important difference in pain outcome measures. Pain 88(3), 287\u2013294 (2000).","journal-title":"Pain"},{"issue":"1\u20132","key":"54906_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","volume":"113","author":"RH Dworkin","year":"2005","unstructured":"Dworkin, R. H. et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113(1\u20132), 9\u201319 (2005).","journal-title":"Pain"},{"issue":"2","key":"54906_CR56","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1179\/crn.2008.017","volume":"26","author":"L Guarda-Nardini","year":"2008","unstructured":"Guarda-Nardini, L. et al. Efficacy of botulinum toxin in treating myofascial pain in bruxers: A controlled placebo pilot study. Cranio 26(2), 126\u2013135 (2008).","journal-title":"Cranio"},{"issue":"14","key":"54906_CR57","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1523\/JNEUROSCI.0375-08.2008","volume":"28","author":"F Antonucci","year":"2008","unstructured":"Antonucci, F. et al. Long-distance retrograde effects of botulinum neurotoxin A. J. Neurosci. 28(14), 3689\u20133696 (2008).","journal-title":"J. Neurosci."},{"issue":"44","key":"54906_CR58","doi-asserted-by":"publisher","first-page":"15650","DOI":"10.1523\/JNEUROSCI.2618-11.2011","volume":"31","author":"L Restani","year":"2011","unstructured":"Restani, L. et al. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT\/A). J. Neurosci. 31(44), 15650\u201315659 (2011).","journal-title":"J. Neurosci."},{"issue":"10","key":"54906_CR59","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/toxins14100704","volume":"14","author":"S Luvisetto","year":"2022","unstructured":"Luvisetto, S. Botulinum neurotoxins beyond neurons: Interplay with glial cells. Toxins (Basel) 14(10), 704 (2022).","journal-title":"Toxins (Basel)"},{"issue":"3","key":"54906_CR60","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0304-3959(01)00284-6","volume":"92","author":"P Svensson","year":"2001","unstructured":"Svensson, P., List, T. & Hector, G. Analysis of stimulus-evoked pain in patients with myofascial temporomandibular pain disorders. Pain 92(3), 399\u2013409 (2001).","journal-title":"Pain"},{"issue":"3","key":"54906_CR61","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0304-3959(03)00095-2","volume":"102","author":"E Sarlani","year":"2003","unstructured":"Sarlani, E. & Greenspan, J. D. Evidence for generalized hyperalgesia in temporomandibular disorders patients. Pain 102(3), 221\u2013226 (2003).","journal-title":"Pain"},{"issue":"2","key":"54906_CR62","first-page":"161","volume":"25","author":"R Matos","year":"2011","unstructured":"Matos, R. et al. Quantitative sensory testing in the trigeminal region: Site and gender differences. J Orofac Pain 25(2), 161\u2013169 (2011).","journal-title":"J Orofac Pain"},{"issue":"3","key":"54906_CR63","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.pain.2008.12.027","volume":"143","author":"CD King","year":"2009","unstructured":"King, C. D. et al. Deficiency in endogenous modulation of prolonged heat pain in patients with Irritable bowel syndrome and temporomandibular disorder. Pain 143(3), 172\u2013178 (2009).","journal-title":"Pain"},{"issue":"10","key":"54906_CR64","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1007\/s00221-014-3997-7","volume":"232","author":"Y Oono","year":"2014","unstructured":"Oono, Y. et al. Conditioned pain modulation in temporomandibular disorders (TMD) pain patients. Exp Brain Res 232(10), 3111\u20133119 (2014).","journal-title":"Exp Brain Res"},{"issue":"11","key":"54906_CR65","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/joor.13081","volume":"47","author":"RL Poluha","year":"2020","unstructured":"Poluha, R. L. et al. Somatosensory and psychosocial profile of patients with painful temporomandibular joint clicking. J Oral Rehabil 47(11), 1346\u20131357 (2020).","journal-title":"J Oral Rehabil"},{"key":"54906_CR66","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.neuropharm.2013.02.011","volume":"70","author":"V Drinovac","year":"2013","unstructured":"Drinovac, V. et al. Involvement of \u03bc-opioid receptors in antinociceptive action of botulinum toxin type A. Neuropharmacology 70, 331\u2013337 (2013).","journal-title":"Neuropharmacology"},{"issue":"3","key":"54906_CR67","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/ejp.1146","volume":"22","author":"V Drinovac Vlah","year":"2018","unstructured":"Drinovac Vlah, V. et al. Role of central versus peripheral opioid system in antinociceptive and anti-inflammatory effect of botulinum toxin type A in trigeminal region. Eur J Pain 22(3), 583\u2013591 (2018).","journal-title":"Eur J Pain"},{"issue":"5","key":"54906_CR68","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ejp.995","volume":"21","author":"C Favre-Guilmard","year":"2017","unstructured":"Favre-Guilmard, C., Chabrier, P. E. & Kalinichev, M. Bilateral analgesic effects of abobotulinumtoxinA (Dysport(\u00ae)) following unilateral administration in the rat. Eur. J. Pain 21(5), 927\u2013937 (2017).","journal-title":"Eur. J. Pain"},{"issue":"11","key":"54906_CR69","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/joor.12685","volume":"45","author":"CG De La Torre","year":"2018","unstructured":"De La Torre, C. G. et al. Prevalence of psychosocial impairment in temporomandibular disorder patients: A systematic review. J. Oral Rehabil. 45(11), 881\u2013889 (2018).","journal-title":"J. Oral Rehabil."},{"issue":"1","key":"54906_CR70","first-page":"3","volume":"20","author":"D Bitiniene","year":"2018","unstructured":"Bitiniene, D. et al. Quality of life in patients with temporomandibular disorders. A systematic review. Stomatologija 20(1), 3\u20139 (2018).","journal-title":"Stomatologija"},{"issue":"4","key":"54906_CR71","doi-asserted-by":"publisher","first-page":"379","DOI":"10.11607\/ofph.2637","volume":"34","author":"B H\u00e4ggman-Henrikson","year":"2020","unstructured":"H\u00e4ggman-Henrikson, B. et al. Impact of catastrophizing in patients with temporomandibular disorders-A systematic review. J. Oral Fac. Pain Headache 34(4), 379\u2013397 (2020).","journal-title":"J. Oral Fac. Pain Headache"},{"issue":"12","key":"54906_CR72","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/joor.13265","volume":"48","author":"CC Roithmann","year":"2021","unstructured":"Roithmann, C. C. et al. Subjective sleep quality and temporomandibular disorders: Systematic literature review and meta-analysis. J. Oral Rehabil. 48(12), 1380\u20131394 (2021).","journal-title":"J. Oral Rehabil."},{"issue":"7","key":"54906_CR73","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/joor.13331","volume":"49","author":"PHF Reis","year":"2022","unstructured":"Reis, P. H. F. et al. Distribution of anxiety and depression among different subtypes of temporomandibular disorder: A systematic review and meta-analysis. J. Oral Rehabilit. 49(7), 754\u2013767 (2022).","journal-title":"J. Oral Rehabilit."},{"issue":"4","key":"54906_CR74","doi-asserted-by":"crossref","first-page":"288","DOI":"10.11607\/ofph.2917","volume":"35","author":"CG De la Torre","year":"2021","unstructured":"De la Torre, C. G. et al. Effects of botulinum toxin type A on the psychosocial features of myofascial pain TMD subjects: A randomized controlled trial. J. Oral Fac. Pain Headache 35(4), 288\u2013296 (2021).","journal-title":"J. Oral Fac. Pain Headache"},{"issue":"4","key":"54906_CR75","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3109\/00207454.2015.1019624","volume":"126","author":"JH Xia","year":"2016","unstructured":"Xia, J. H. et al. Botulinum toxin A in the treatment of trigeminal neuralgia. Int J Neurosci 126(4), 348\u2013353 (2016).","journal-title":"Int J Neurosci"},{"issue":"3","key":"54906_CR76","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jnnp-2018-319290","volume":"90","author":"AM Blumenfeld","year":"2019","unstructured":"Blumenfeld, A. M. et al. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. J Neurol Neurosurg Psychiatry 90(3), 353\u2013360 (2019).","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"54906_CR77","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jpsychires.2012.01.027","volume":"46","author":"MA Wollmer","year":"2012","unstructured":"Wollmer, M. A. et al. Facing depression with botulinum toxin: A randomized controlled trial. J Psychiatr Res 46(5), 574\u2013581 (2012).","journal-title":"J Psychiatr Res"},{"issue":"7","key":"54906_CR78","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/dsu.12175","volume":"39","author":"D Hexsel","year":"2013","unstructured":"Hexsel, D. et al. Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxin A for glabellar lines. Dermatol. Surg. 39(7), 1088\u20131096 (2013).","journal-title":"Dermatol. Surg."},{"issue":"8","key":"54906_CR79","doi-asserted-by":"publisher","first-page":"837","DOI":"10.4088\/JCP.13m08845","volume":"75","author":"M Magid","year":"2014","unstructured":"Magid, M. et al. Treatment of major depressive disorder using botulinum toxin A: A 24-week randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 75(8), 837\u2013844 (2014).","journal-title":"J. Clin. Psychiatry"},{"key":"54906_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2013.11.006","volume":"52","author":"E Finzi","year":"2014","unstructured":"Finzi, E. & Rosenthal, N. E. Treatment of depression with onabotulinumtoxin A: A randomized, double-blind, placebo controlled trial. J. Psychiatr. Res. 52, 1\u20136 (2014).","journal-title":"J. Psychiatr. Res."},{"issue":"11\u201312","key":"54906_CR81","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.jpain.2020.03.005","volume":"21","author":"A Zajacova","year":"2020","unstructured":"Zajacova, A., Rogers, R. G., Grodsky, E. & Grol-Prokopczyk, H. The relationship between education and pain among adults aged 30\u201349 in the United States. J Pain. 21(11\u201312), 1270\u20131280. https:\/\/doi.org\/10.1016\/j.jpain.2020.03.005 (2020).","journal-title":"J Pain."},{"issue":"11","key":"54906_CR82","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/toxins14110741","volume":"14","author":"CG De la Torre","year":"2022","unstructured":"De la Torre, C. G. et al. Long-term effects of a single application of botulinum toxin type A in temporomandibular myofascial pain patients: A controlled clinical trial. Toxins (Basel) 14(11), 741 (2022).","journal-title":"Toxins (Basel)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-54906-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-54906-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-54906-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T13:21:38Z","timestamp":1708435298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-54906-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54906"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-54906-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4201"}}